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Summary and future perspectives
In this thesis we investigated whether multidrug resistance-associated 
protein 1 (MRP1) levels in bronchi and parenchymal lung tissue are related 
to chronic obstructive pulmonary disease (COPD) development. MRP1 is a 
protective protein against toxic substances and oxidative stress in which 
glutathione (GSH) plays a central role [1, 2]. MRP1 is highly expressed in 
lung airway epithelium and might be important with respect to protection 
against inhaled toxic substances. Development of COPD is highly related 
to smoking and is, amongst others, characterized by an imbalance between 
oxidants and antioxidants [3]. Diminished MRP1 function may therefore 
predispose smokers to a higher susceptibility to COPD [4].
 After the general introduction of this thesis, in chapter two, we 
reviewed available knowledge on ATP-binding cassette (ABC) transporters 
that are expressed in the lung and speculated about their potential role in 
normal lung function but also in the pathological situation. So far, ABC 
transporters have hardly been investigated in prevalent lung diseases such 
as asthma and COPD. Three pulmonary diseases have been described 
previously to be caused by mutations in ABC transporters, i.e. cystic 
ﬁbrosis, Tangier disease and fatal surfactant deﬁciency. Several pulmonary 
drugs are substrates for ABC transporters, thus, interindividual variation 
in functional activity of these transporters is likely to affect drug treatment 
of lung diseases. Amongst 20 different tissues, the lung and trachea were 
identiﬁed to have high transcriptional activity for many ABC transporters 
[5]. According to this survey of the literature, the most important ABC 
transporters in bronchial epithelium are MRP1, P-glycoprotein (P-gp), 
breast cancer resistance protein (BCRP) and cystic ﬁbrosis transmembrane 
conductance regulator (CFTR). Conﬂicting results exist about MRP2, 3, 4 and 
5. MRP1 is also present in bronchoalveolar lavage inﬂammatory cells (mainly 
macrophages), goblet cells and possibly in alveolar type I cells. It remains 
to be determined whether MRP2, 3, 4, 5, P-gp and CFTR are expressed 
in alveolar type I cells. The most important ABC transporters in alveolar 
type II cells are ABCA1 and ABCA3 and these proteins appear to play an 
important role in the production of surfactant. Lung endothelial cells are 
BCRP positive but results on P-gp are inconclusive. In summary, mutations 
and polymorphisms in ABC transporters may have important clinical 
consequences for development of lung diseases. Insight in the function of 









 In chapter three, MRP1, P-gp and LRP (lung resistance-related 
protein) protein expression was determined in lung sections of COPD patients 
and controls in a semi-quantitative manner. We detected lower levels of 
MRP1 in bronchial epithelium of COPD patients (n=11) compared to healthy 
controls (n=8) and also lower MRP1 expression in severe and very severe 
COPD (n=10) compared to mild and moderate COPD (n=9). P-gp and LRP 
did not differ between groups. Expression levels did not correlate with lung 
function parameters or pack-years smoked. These results indicate that 
diminished MRP1 expression is indeed related to COPD and that lower levels 
are related to more severe disease. It would be of great interest to investigate 
a larger group of patients with disease severity from mild to severe to verify 
our results and to investigate a potential relationship of MRP1 expression 
levels with inﬂammation and remodeling markers pertinent to COPD 
development. 
In chapter four, we questioned whether MRP1 transcriptional 
expression levels and functional MRP1 mediated transport differs between 
bronchial epithelial cells derived from healthy and severe COPD lung tissue. 
MRP1 expression is higher in bronchial epithelial cells from six healthy 
donor lungs compared to the native lung from the same individual with 
severe COPD who underwent lung transplantation. A comparable trend was 
found for MRP1 activity which was analyzed in four patients. In addition, 
both MRP1 expression and MRP1 activity correlated well in cells from the 
native and donor part of the bronchi. This study is in line with the results 
of chapter 2 in which we describe a higher MRP1 expression in biopsies of 
healthy individuals compared to COPD patients. This approach provides the 
unique opportunity to analyze differences in MRP1 expression in healthy 
and COPD bronchi irrespective of external inﬂuences such as current smoke 
exposure and use of medication. Thus, there are indications that a lower 
MRP1 activity is related to development of COPD.
 In chapter ﬁve, we aimed to determine whether absence of MRP1 
and P-gp plays a role in vivo in cigarette smoke induced emphysema and 
pulmonary inﬂammation. We found that the pulmonary inﬂammatory 
response is reduced in lungs of Mrp1/Mdr1a/Mdr1b triple knockout (TKO) 
mice after six months of smoke exposure compared to wildtype mice. This 
was reﬂected by a reduction of inﬂammatory cells and reduced IL-8 levels 
in lungs of TKO mice with a trend for reduced GM-CSF. It remains to be 
investigated whether this effect is positive or negative with respect to lung 
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diseases because inﬂammation contributes to the development of COPD, 
but inﬂammation is also necessary for lung repair. Six months smoking did 
not induce lung emphysema in neither wildtype nor Mrp1/Mdr1a/Mdr1b 
deﬁcient mice. This may be due to a low susceptibility of this mice strain 
(FVB mice) to develop lung emphysema. In further studies, more than six 
months of smoke exposure would be recommended to induce emphysema 
in these mice. Otherwise, it is suggested to backcross the TKO mice to 
a mouse strain that is more prone to develop emphysema. In addition, 
smoke exposure of the Mrp1 single knockout mice and the P-gp (Mdr1a/1b) 
knockout mice should be performed to unravel the contribution of the 
separate efﬂux pumps by comparing the effects to wildype mice.
 Since our data suggest that MRP1 expression is associated with 
COPD, we set out to test whether cigarette smoke extract (CSE) affects 
MRP1 mediated activity (chapter six). The in vitro effects of cigarette smoke 
exposure have been analyzed in the bronchial epithelial cell line 16HBE14o-
. The main results were that CSE inhibits MRP1 functional activity and 
that cell survival after CSE incubation is decreased when MRP1 activity is 
blocked. In contrast, inhibition of P-gp and BCRP did not affect cell survival. 
These data strongly suggest that MRP1 function is affected by smoking and 
that MRP1 is important for cell survival to resist cigarette smoke toxicity. 
If MRP1 is cytoprotective for lung function, it is of clinical interest to 
investigate the effect of pulmonary drugs prescribed to COPD patients on 
MRP1. Chapter seven describes the effects of COPD treatments on MRP1 
functional activity in the bronchial epithelial cell line 16HBE14o-. Budesonide 
inhibited MRP1 activity, whereas formoterol had no signiﬁcant effects. 
Interestingly, simultaneous incubation of budesonide and formoterol resulted 
in a lower MRP1 inhibition than budesonide alone. Clinical studies have 
shown that treatment of COPD patients with a combination of corticosteroids 
(e.g. budesonide) and long-acting beta-mimetics (e.g. formoterol) are capable 
to reduce the number of exacerbations. Further research is necessary 
to investigate whether the effects on MRP1 function contribute to these 
observations that are beneﬁcial to COPD prognosis. With N-acetylcysteine 
we found stimulation of MRP1 activity in a concentration dependent manner 
and a similar tendency for ipratropium bromide. These results indicate that 
with respect to MRP1, a combination of budesonide and formoterol could be 
beneﬁcial for treatment of COPD patients compared to single treatment with 
budesonide. In addition, the stimulation of MRP1 activity with ipratropium 








COPD. Each investigated drug has its particular proven positive effects for 
COPD patients; the results of our study on MRP1 function give additional 
information on putative (side)-effects of these drugs, which should be taken 
into account.
In chapter eight, it was studied if incubation with indomethacin, 
a non-steroidal anti-inﬂammatory drug, can circumvent drug resistance 
in an MRP1 overexpressing small cell lung cancer cell line. Small cell lung 
cancer initially responds well to chemotherapy but often become resistant 
at recurrence. Indomethacin is an inhibitor of MRP1 function. Surprisingly, 
cells with low MRP1 expression were more resistant to indomethacin than 
cells with high MRP1 levels, as determined with cell survival and apoptosis 
assays. We found that indomethacin decreased GSH levels in MRP1 
overexpressing cells. This was accompanied by a decrease in mitochondrial 
membrane potential, and altogether made these cells less resistant against 
cellular stress induction. This mechanism could potentially be exploited 
for treatment of lung cancer in which either intrinsic or extrinsic multidrug 
resistance caused by MRP1 overexpression plays a role. 
Future perspectives
This is the ﬁrst study in which MDR proteins were investigated with respect 
to their role in COPD development. The results of our patient studies, in vitro 
experiments and animal studies, show a potential role for MRP1 (and maybe 
P-gp as well) in COPD development and in the handling of cigarette smoke. 
Further investigation is required to determine the underlying mechanisms. 
Polymorphisms in the MRP1 gene locus have been identiﬁed and 
this might lead to different MRP1 functional activity and thus to different 
responses to certain drugs between individuals [6]. Until now, the 
pharmacological implications and phenotypical consequences of individual 
variations in MRP1 function are speculative [7, 8]. Recently, it was reported 
that polymorphisms in MRP1 are associated with increased risk of ovarian 
cancer [9]. It can be hypothesized that functional polymorphisms in MRP1 
are related to development of COPD. Thus, it would be of great interest to 
determine polymorphism frequencies in COPD populations compared to 
individuals without pulmonary diseases. Another aspect is that interaction 
with (protection against) oxidative stress factors can be studied. It is for 
instance known that reduced fruit and/or vitamin intake is associated 
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with lower lung function, a characteristic of COPD. Thus gene-environment 
interaction could be studied as to polymorphisms in MRP1 and dietary 
habits. Furthermore the possibility can be explored whether MRP1 activity 
is related to disease susceptibility, but also whether its function is related 
to disease severity and/or progression. This is possible by association with 
lung function decline, stage of COPD (airway versus parenchymal disease) 
and inﬂammatory and remodeling markers. In addition, single nucleotide 
polymorphisms in other MDR proteins such as P-gp and BCRP would 
be of interest in this respect because these transporters are also present 
in high to moderate levels in human lungs. Other enzymes important in 
detoxiﬁcation processes are members of the glutathione S-transferase (GST) 
family. The function of GSTs is detoxiﬁcation of a broad range of substances 
by conjugation to GSH, and many of these GSH-conjugates are transported 
out of the cell by MRP1 [1]. Polymorphisms in GST genes are associated with 
COPD and a rapid decline in lung function of smokers [10, 11]. Because 
MRP1 and GST function are strongly related, it would be of great interest 
to study whether polymorphisms in MRP1 are associated with development 
of COPD and/or decline of lung function compared to individuals without a 
history of pulmonary diseases and whether functional interaction between 
GST and MDR genes enhances the effects of polymorphisms in these 
individual genes. 
At present, techniques used in genomics or proteomics are still 
improving and can be of great use for further research. With a micro-array, 
the expression of all 48 ABC transporters can be determined at the mRNA 
level in one assay. In addition, mRNA expression levels of genes that are 
involved in detoxiﬁcation, such as enzymes involved in oxidative stress (e.g. 
GSH metabolism proteins) or enzymes from the cytochrome P450 family can 
be measured. Patient materials (biopsies, primary cells) can be analyzed with 
these techniques to compare mRNA or protein expressions with material 
from healthy individuals. Using in vitro models by incubating lung cells 
with smoke extract, identiﬁcation is possible of the genes (or proteins) that 
are differentially expressed. The bronchial epithelial cell line 16HBE14o- is 
very suitable for drug transport studies when compared to other cell lines 
since its permeability properties are comparable to those reported in native 
lung epithelial cells [12]. For example, 16HBE14o- cells form tight junctions 
and have the ability to develop cilia under certain culture conditions. It was 
already known that these cells express CFTR [13], and functional expression 








line was characterized for expression of MRPs and BCRP. We found that 
MRP1 expression was very high in these cells, like in primary bronchial 
cells. It would be of special interest to analyze expression of all known ABC 
transporter proteins in these immortalized cells and to investigate which 
proteins are affected by cigarette smoke by exposing cells to cigarette smoke 
extract. For comparison, cancer cell lines and primary lung epithelial cells 
can be used to validate the model. Thus, exposing these cells to cigarette 
smoke, isolation of protein and RNA, and performing microarrays and real-
time PCR will give insight in which (MDR) proteins, besides MRP1, play a role 
in cigarette smoke detoxiﬁcation. Many substances in cigarette smoke are 
carcinogenic or mutagenic. Therefore, the potential protective role of MRP1 
in development of lung cancer would be of signiﬁcant interest besides its role 
in COPD. Smoke exposure can be performed using cigarette smoke extract 
(liquid smoke), as was applied in our study, or exposure to gaseous cigarette 
smoke in an air-liquid interface experimental setup. Using 16HBE14o- cells 
in this setup would be a good model because these cells are known to develop 
cilia when they are grown in an air-liquid transwell system resembling the in 
vivo natural situation [12]. 
RNA interference was used in the current thesis to downregulate 
MRP1 expression in 16HBE14o- cells to study modulation of cigarette smoke 
toxicity and effects on MRP1 functional activity. Another approach to unravel 
the role of MRP1 and/or P-gp in detoxiﬁcation mechanisms of cigarette 
smoke would be to isolate primary bronchial epithelial cells of lungs of Mrp1/
Mdr1a/1b triple knockout mice or the single knockout mice and incubate 
these cells with cigarette smoke extract for analysis with ﬂow cytometry. 
The advantage of this experiment is that these mice totally lack expression 
of MRP1 instead of transient downregulation with RNA interference. In 
this way, contribution of MRP1 can be studied by e.g. adding back MRP1 
by transfection with MRP1 expression constructs. A major disadvantage is 
that it is difﬁcult to culture these primary cells for more than three to ﬁve 
passages. Also, it has to be taken into account that the permanent absence 
of MRP1 (instead of a decreased function) may induce a non-physiological 
situation by alterations of cellular detoxiﬁcation pathways and compensation 
mechanisms. To investigate the direct and indirect effects on MRP1 
expression of cigarette smoke, experiments with luciferase constructs for 
the MRP1 promoter are invaluable. This system is also useful to determine 
the effects of expression of trancription factors that regulate MRP1, such as 
nuclear factor-E2 p45-related factor (NRF2).
Summary and future perspectives
145
 Animal studies are necessary to analyze the in vivo effects of smoking 
on the cellular level in a controllable way. COPD animal models have been 
developed to this aim. We used a model with mainstream, nose only smoke 
exposure for 6 months, which has been succesfully applied in other studies 
to investigate emphysema development [15]. Signiﬁcant alterations in 
inﬂammation were detected in the lung but we were unable to objectivate 
emphysema development with the commonly applied linear mean (Lm) 
intercept method. This could be due to resistance of this mouse strain 
(FVB) to develop emphysema, since it is well known that large inter-strain 
differences exist with regard to COPD development. For further studies, 
it is suggested to backcross MRP1 knockout mice to a mouse strain that 
is more prone to develop emphysema such as C57Bl6/J or A/J mice to 
assess whether emphysema can be induced in these mice. In this setting, it 
is feasible to study treatment with drugs that e.g. intervene with oxidative 
stress or stimulate MRP1 expression. 
 Not much is known about effects of other pulmonary drugs on 
expression or activity of MRP1 or other ABC transporters [16, 17]. The anti-
inﬂammatory drug montelukast (a leukotriene receptor antagonist) blocks 
the action of leukotrienes and relieves the symptoms of asthma. Interestingly, 
montelukast functionally and structurally resembles the leukotriene 
antagonist MK571, a very potent MRP1 inhibitor. In recent studies, 
montelukast has been used for treatment of COPD patients in clinical trials. 
This treatment had a positive anti-inﬂammatory effect and beneﬁcial effects 
on hypertonic saline-induced airway responsiveness in COPD patients [18, 
19]. Since montelukast is an MRP1 inhibitor, chronic treatment with this 
drug in an experimental (animal) setting might further elucidate the relation 
between MRP1 function and COPD (and possibly asthma [20]) development. 
In conclusion, lower MRP1 expression is related to COPD and pulmonary 
inﬂammation. Cigarette smoke and several pulmonary drugs affect MRP1 
activity. Further studies are required which might lead to therapy based on 
genetic proﬁling to optimize treatment and to reduce negative (long-term) side 
effects. However, to quit smoking is until now still the best therapy that can 
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